ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Top Stocks Set to Outperform
Over the Next 1 to 3 Months.
Click for your free picks >>

Quote:

Search for Ticker

Free Membership

Search:

FOLD: Amicus Therapeutics Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

AMICUS THERAPEUTICS INC (NASD)
FOLD	3.94	0.11	(2.87%)	Vol. 41,351	16:00 ET

AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.

General Information

AMICUS THERAPT

6 Cedar Brook Drive Cranbury, NJ 08512 Phone: 609-662-2000 Fax: 609-662-2001 Web: www.amicustherapeutics.com Email: info@amicustherapeutics.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	02/04/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	3.83
52 Week High	13.50
52 Week Low	3.68
Beta	-0.79
20 Day Moving Average	156,633.45
Target Price Consensus	13.53

% Price Change
4 Week	-8.81
12 Week	-61.51
YTD	-52.01

% Price Change Relative to S&P 500
4 Week	-9.79
12 Week	-63.71
YTD	-60.28

Share Information
Shares Outstanding (millions)	22.64
Market Capitalization (millions)	86.72
Short Ratio	9.67
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.75
Current Year EPS Consensus Estimate	-2.48
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	02/04/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	4.00
30 Days Ago	4.00
60 Days Ago	2.00
90 Days Ago	2.33

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	-63.89%
vs. Previous Quarter	1.67%

Sales Growth
vs. Previous Year	34.49%
vs. Previous Quarter:	-8.36%

Price Ratios
Price/Book	2.33
Price/Cash Flow	-
Price / Sales	4.51

ROE
09/30/09	-98.90
06/30/09	-73.67
03/31/09	-58.03

ROA
09/30/09	-47.43
06/30/09	-38.98
03/31/09	-32.70

Current Ratio
09/30/09	5.48
06/30/09	6.77
03/31/09	8.85

Quick Ratio
09/30/09	5.48
06/30/09	6.77
03/31/09	8.85

Operating Margin
09/30/09	-279.19
06/30/09	-269.55
03/31/09	-268.70

Net Margin
09/30/09	-932.12
06/30/09	-969.16
03/31/09	-1,034.06

Pre-Tax Margin
09/30/09	-932.12
06/30/09	-969.16
03/31/09	-1,034.06

Book Value
09/30/09	1.64
06/30/09	2.15
03/31/09	2.66

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	0.07
06/30/09	0.04
03/31/09	0.00

Debt to Capital
09/30/09	6.75
06/30/09	4.21
03/31/09	0.36


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research